A recent study showed that intensive glucose-lowering therapy was beneficial in preventing incident CAD only in a subset of diabetic patients defined by haptoglobin type, implying that genotypic and/or phenotypic differences can mediate the cardioprotective effects of intensive glucose-lowering therapy93. Here, HP is linked to coronary artery disorder.